Barr Premarin Petition On Misleading Labeling May Be Renewed; ANDA Planned
Executive Summary
Barr will decide by the end of January whether to continue to pursue its citizen petition claiming that labeling for Wyeth-Ayerst's Premarin (conjugated estrogens) is false and misleading
You may also be interested in...
Wyeth Premarin Petition Withdrawn; Firm Hints At Future Action
Wyeth is reserving its right to file future citizen petitions with regard to the manufacturing of generic Premarin (conjugated estrogens), the company says in a letter formally withdrawing a 1994 petition to block synthetically derived estrogens
Wyeth Premarin Petition Withdrawn; Firm Hints At Future Action
Wyeth is reserving its right to file future citizen petitions with regard to the manufacturing of generic Premarin (conjugated estrogens), the company says in a letter formally withdrawing a 1994 petition to block synthetically derived estrogens
Barr Generic Premarin Development Plan Includes Exclusive Supply Deal
Barr anticipates that its exclusive supply agreement with Natural Biologics will permit pricing of its Premarin generic as a single-source generic